Alliance Pharma acquires Nizoral rights in APAC region

Alliance Pharma plc (AIM: APH), the specialty pharmaceutical company, is pleased to announce that it has agreed to acquire exclusive marketing rights to Nizoral, a medical, anti-dandruff shampoo brand, in Asia-Pacific ("APAC") (the "Nizoral Rights") from Janssen Pharmaceutica NV (a member of the Johnson & Johnson group of companies) (the "Vendor") for a total consideration of £60.0 million (the "Acquisition").

The Acquisition, which will boost Alliance's successful and rapidly growing APAC distributor business, is expected to generate material earnings enhancement in the first full year of ownership.

The Acquisition will be funded by an underwritten equity placing of new ordinary shares in the capital of the Company to raise gross proceeds of £34.0 million (c. £32.1 million net of transaction expenses) (the "Placing") at an indicative placing price of 91 pence per Placing Share, to be confirmed pursuant to an accelerated bookbuild process, and by the draw down of c.£27.9 million of a £35.0 million extension of the Group's debt facilities. The Placing is being conducted by means of an accelerated bookbuild process, which will be launched immediately following this announcement.

Transaction highlights
• Alliance has agreed to acquire Nizoral, a medical, anti-dandruff shampoo brand, in the APAC region from Janssen Pharmaceutica NV for a total consideration of £60 million payable to the Vendor on completion
• The consideration will be funded by a combination of the underwritten Placing to raise net proceeds of c.£32.1 million and c.£27.9 million in debt
• The Nizoral Rights include more than 15 countries including Japan, Thailand, South Korea, China and Pacific markets
• In 2017, the Nizoral Rights achieved net sales of £18.5 million1 in APAC
• Taking into account Alliance's anticipated costs, the Nizoral Rights would have generated EBITDA on a pro forma basis in APAC ("Pro Forma EBITDA") of £7.1 million in 2017
• The Acquisition boosts Alliance's exposure to fast-growing APAC markets and will enhance Alliance's APAC distributor footprint
• Nizoral will represent Alliance's fourth International Star brand, complementing Kelo-cote™, MacuShield™ and Vamousse™
• The Acquisition is expected to generate material earnings enhancement in the first full year of ownership
1 Currency conversion rate: £1.00 = USD1.3528


Peter Butterfield, Chief Executive Officer of Alliance, commented:

"Asia-Pacific is Alliance's fastest-growing region and we are delighted to strengthen the development of our APAC business through this earnings-enhancing acquisition of Nizoral, an excellent brand with a long medical heritage. Nizoral has significant sales, profits and growth potential in the APAC region and will become the fourth International Star brand in our product portfolio."

For further information:

Alliance Pharma plc Tel: +44 (0) 1249 466 966
Peter Butterfield, Chief Executive Officer
Andrew Franklin, Chief Financial Officer
www.alliancepharma.co.uk

Numis Securities Limited Tel: +44 (0) 20 7260 1000
Nominated Adviser: Michael Meade / Freddie Barnfield / Freddie Naylor-Leyland
Corporate Broking: James Black

Investec Bank plc Tel: +44 (0) 20 7597 5970
Corporate Finance: Daniel Adams
Corporate Broking: Patrick Robb / David Herring

Buchanan Tel: +44 (0) 20 7466 5000
Mark Court / Sophie Wills / Gemma Mostyn-Owen
alliancepharma@buchanan.uk.com

Alliance Pharma plc

Alliance Pharma plc
Legacy pharmaceutical products

Downloads

DownloadPress Release

Latest News

MVM announces partial sale of its holding in Ambio

MVM Partners announces the partial sale of its holding in Ambio to The Carlyle Group

Alliance Pharma acquires Nizoral rights in APAC region

Alliance Pharma plc (AIM: APH), the specialty pharmaceutical company, is pleased to announce that it has agreed to acquire exclusive marketing rights to Nizoral, a medical, anti-dandruff shampoo brand, in Asia-Pacific from Janssen Pharmaceutica NV.

Alliance Pharma receives positive opinion for Diclectin

Alliance Pharma plc (AIM: APH), the specialty pharmaceutical company, announces that, following discussions with the Medicines and Healthcare products Regulatory Agency and the Commission on Human Medicines, the Marketing Authorisation Application for Diclectin® is now considered approvable.

Wilson Therapeutics AB announces public offer from Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc., has today, through Alexion Pharma Nordics Holding AB, announced a public cash offer to Wilson Therapeutics’ shareholders for a consideration of SEK 232 per Wilson Therapeutics share in cash (the “Offer”), which corresponds to a total offer value of approximately SEK 6,564 million, based on 28,292,272 shares outstanding.

Clinical study supports the use of Cheetah Medical's technologies

Cheetah Medical, a leader in non-invasive hemodynamic monitoring, has announced the publication of a major clinical study designed to evaluate stroke volume guided resuscitation in ICU patients with severe sepsis and septic shock

Vertos Medical Secures $28m in Latest Round of Funding

Vertos Medical Inc., a leader in the minimally invasive treatment of lumbar spinal stenosis has announced that it has completed a $28 million financing round.